Combretastatin A4-phosphate and its potential in veterinary oncology: a review

Veterinary and Comparative Oncology

Volumn 15, Issue 1, 2017, Pages 184-193

  Abma, E ^a   Daminet, S ^a   Smets, P ^a   Ni, Y ^b   de Rooster, H ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

anticancer therapy; combretastatin A4 phosphate; tubulin binding agent; vascular disrupting agent

Indexed keywords

ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; COMBRETASTATIN;

ANIMAL; DOG; DOG DISEASES; HUMAN; MOUSE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLOGY; PROCEDURES; VETERINARY; VETERINARY MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; DOG DISEASES; DOGS; HUMANS; MEDICAL ONCOLOGY; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VETERINARY MEDICINE;

EID: 84929773897     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12150     Document Type: Article

References (72)

1. Chaplin DJ, Pettit GR, Parkins CS and Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. British Journal of Cancer 1996; 74: s86–s88.
2. Chaplin DJ, Pettit GR and Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Research 1999; 19: 189–196.
3. Horsman MR and Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Research 2006; 66: 11520–11539.
4. Tozer G, Kanthou C, Parkins CS and Hill SA. The biology of the combretastatins as tumour vascular targeting agents. International Journal of Experimental Pathology 2002; 83: 21–38.
5. Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, et al. A phase II trial of Fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19: 233–240.
6. Garon EB, Kabbinavar FF, Neidhart JA, Neidhart JD, Gabrail NY, Oliveira MR, et al. Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): the FALCON trial. Journal of Clinical Oncology 2010; 28: 7587.
7. Ng Q-S, Mandeville H, Goh V, Alonzi R, Milner J, Carnell D, et al. Phase Ib of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of Oncology 2012; 23: 231–237.
8. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu S-P, Bal C, et al. Randomized safety and efficacy study of Fosbretabulin with Paclitaxel/Carboplatin against anaplastic thyroid carcinoma. Thyroid 2014; 24: 232–240.
9. Kador PF, Blessing K, Randazzo J, Makita J and Wyman M. Evaluation of the vascular targeting agent combretastatin A-4 prodrug on retinal neovascularization in the galactose-fed dog. Journal of Ocular Pharmacology and Therapeutics 2007; 23: 132–142.
10. Wang X, Chen Z, Che J, Meng Q, Shan C, Hou Y, et al. Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study. Journal of Chromatography B 2009; 877: 3813–3821.
11. Siemann DW, Chaplin DJ and Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491–2499.
12. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.
13. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nature 2003; 3: 401–410.
14. Denekamp J, Hill SA and Hobson B. Vascular occlusion and tumour cell death. European Journal of Cancer 1983; 19: 271–275.
15. Chaplin DJ and Horsman MR. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiotherapy and Oncology 1994; 30: 59–65.
16. Parkins CS, Hill SA, Lonergan SJ, Horsman MR, Chadwick JA and Chaplin DJ. Ischaemia induced cell death in tumors: importance of temperature and pH. International Journal of Radioation Oncology, Biology, Physics 1994; 29: 499–503.
17. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. British Journal of Cancer 1892; 45: 136–139.
18. Griggs J, Metcalfe JC and Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. The Lancet Oncology 2001; 2: 82–87.
19. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. Journal of Clinical Investigation 2005; 115: 2992–3006.
20. Kakolyris S, Fox SB, Koukourakis M, Giatromanolaki A, Brown N, Leek RD, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. British Journal of Cancer 2000; 82: 844–851.
21. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treatment Reviews 2011; 37: 63–74.
22. Bloemendal HJ, Logtenberg T and Voest EE. New strategies in anti-vascular cancer therapy. European Journal of Clinical Investigation 1999; 29: 802–809.
23. Chaplin DJ and Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. International Journal of Radioation Oncology, Biology, Physics 2002; 54: 1491–1496.
24. Denekamp J and Hill SA. Angiogenic attack as a therapeutic strategy for cancer. Radiotherapy and Oncology 1991; 20: 103–112.
25. Hayes AJ, Li LY and Lippman ME. Anti-vascular therapy: a new approach to cancer treatment. Western Journal of Medicine 2000; 172: 39–42.
26. Horsman MR, Bohn AB and Busk M. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Experimental Oncology 2010; 32: 143–148.
27. Raben D and Ryan A. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? Clinical Lung Cancer 2005; 7: 175–179.
28. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 209–210.
29. Tozer G, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Research 1999; 59: 1626–1634.
30. Tozer G, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Research 2001; 61: 6413–6422.
31. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Research 1997; 57: 1829–1834.
32. Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate pro-drug. British Journal of Cancer 1999; 81: 1318–1327.
33. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imanging. Journal of Clinical Oncology 2003; 21: 2831–2842.
34. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492–499.
35. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, et al. Treatment of rodent liver tumor with combretastatin A4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Investigative Radiology 2009; 44: 44–53.
36. Li J, Sun Z, Zhang J, Shao H, Cona MM, Wang H, et al. A dual-targeting anticancer approach: soil and seed principle. Radiology 2011; 260: 799–807.
37. Anderson H, Yap J, Miller M, Robbins A, Jones T and Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phospate. Journal of Clinical Oncology 2003; 21: 2823–2830.
38. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day scedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. Journal of Clinical Oncology 2003; 21: 4428–4438.
39. Hamel E. Antimitotic natural products and their interactions with tubulin. Medicinal Research Reviews 1996; 16: 207–231.
40. Tozer G, Kanthou C and Baguley BC. Disrupting tumour blood vessels. Nature 2005; 5: 423–435.
41. Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate. Pharmacology and Toxicology 2013; 14: 1–10.
42. Li L, Rojiani A and Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. International Journal of Radioation Oncology, Biology, Physics 1998; 42: 899–903.
43. Eikesdal HP, Schem B-C, Mella O and Dahl O. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radioation Oncology, Biology, Physics 2000; 46: 645–652.
44. Ke Q, Bodyak N, Rigor DL, Hurst NW, Chaplin DJ and Kang PM. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vascular Pharmacology 2009; 51: 337–343.
45. Busk M, Bohn AB, Skals M, Wang T and Horsman MR. Combretastatin-induced hypertension and the consequences for its combination with other therapies. Vascular Pharmacology 2011; 54: 13–17.
46. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L and Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. European Journal of Cancer 1991; 27: 482–487.
47. Hill SA, Lonergan SJ, Denekamp J and Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. European Journal of Cancer 1993; 29A: 1320–1324.
48. Dowlati A, Robertson K, Cooney MM, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Research 2002; 62: 3408–3416.
49. Rustin GJS, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. Journal of Clinical Oncology 2003; 21: 2815–2822.
50. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Cancer Research 2004; 10: 96–100.
51. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0, 2009; NIH publication No. 09-5410.
52. US Department of Health and Human Services. Seventh Report of the Joint National Committee (JNC-7). Prevention, detection, evaluation, and treatment of high blood pressure. 2003; NIH publication No. 03-5233.
53. Siemann DW, Chaplin DJ and Walicke PA. A review and update of the current status of the vasculature disabling agent combretastatin-A4 phosphate (CA4P). Expert Opinion on Investigational Drugs 2009; 18: 189–197.
54. Albers JW, Chaudhry AJW, Cavaletti V and Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. The Cochrane Database of Systematic Reviews 2014: 3:1–74.
55. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–936.
56. Papetti M and Herman IM. Mechanisms of normal and tumor-derived angiogenesis. American Journal of Physiology-Cell Physiology 2002; 282: 947–970.
57. Lijnen HR. Angiogenesis and obesity. Cardiovascular Research 2008; 78: 286–293.
58. Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A and Levi-Schaffer F. Angiogenesis in asthma. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2009; 39: 1815–1821.
59. Griggs J, Hesketh R, Smith GA, Brindle KM, Metcalfe JC, Thomas GA, et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. British Journal of Cancer 2001; 84: 832–835.
60. Brown S, Atkins C, Bagley R, Carr A, Cowgill L, Davidson M, et al. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Journal of Veterinary Internal Medicine 2007; 21: 542–558.
61. Siemann DW and Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Seminars in Radiation Oncology 2003; 13: 53–61.
62. Boehm T, Folkman J, Browder T and O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.
63. Murata R, Siemann DW, Overgaard J and Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiotherapy and Oncology 2001; 60: 155–161.
64. Eikesdal HP, Bjerkvig R, Mella O and Dahl O. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology 2001; 60: 147–154.
65. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Research 2001; 61: 4716–4722.
66. Rustin GJS, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, et al. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patiens with advanced cancer. British Journal of Cancer 2010; 102: 1355–1360.
67. Li J, Cona MM, Chen F, Feng Y, Zhou L, Yu J, et al. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics 2012; 2: 1010–1019.
68. Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine: Nanotechnology, Biology and Medicine 2012; 8: 81–92.
69. Li J, Cona MM, Chen F, Feng Y, Zhou L, Zhang G, et al. Sequential systemic administrations of combretastatin A4 phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics 2013; 3: 127–137.
70. Cona MM, Koole M, Feng Y, Liu Y, Verbruggen A, Oyen R, et al. Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic. International Journal of Oncology 2014; 44: 819–829.
71. th edn., SJ Withrow and DM Vail Eds., Edinburgh, Elsevier Saunders, 2007: 327–333.
72. Siemann DW, Warrington KH and Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiotherapy and Oncology 2000; 57: 5–12.